Skip to main content

Metastatic Non-Small Cell Lung Cancer COPERNICUS

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sacramento
  • Auburn
  • Roseville

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Deepti Behl
Deepti Behl
Principal investigator
View Profile
Ryan F. Kendle
Ryan F. Kendle
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?